List of experts and groups consulted in the development of datasharing measures
The below non-industry and industry reviewers read and provided feedback on the draft datasharing measures. The patient representatives discussed the measures at an in-person roundtable. The final measures do not necessarily represent the views of any particular reviewer.
Non-Industry Reviewers Organization
Deputy Standard goes beyond what is required for legal compliance. Our goal is to inspire companies to move towards a set of practices that make available information that is sufficient to achieve the major benefits associated with clinical trial data sharing. Recognizing that companies currently confront a landscape of multiple, sometimes conflicting data sharing standards, our objective was also to synthesize the best thinking and offer a harmonized standard that is both measurable and broadly consistent with other prominent standards.
Standard

Covered Trials:
This Standard applies to all Phase 2 and 3 clinical trials that were included in a successful drug or biologic application for US FDA approval (i.e., submitted in support of a new drug application (NDA) or biologic license application (BLA)), except expanded access trials, trials withdrawn or terminated without having enrolled participants, and trials relating to an indication other than the indication for which approval was sought.
a. If concerned that sharing data for a particular trial involves a high risk of reidentifying individual patients due to small enrollment or other factors, companies may seek an exclusion for the trial by sending the GPS Project team an explanation and an attestation that a statistician believes the risk of reidentification is unacceptably high.
b. If more than one company was involved in the development of a drug, the NDA holder is presumptively responsible for meeting this standard for all Covered Trials. However, a trial can be reassigned to another company if the NDA holder states that another company controls the data and should therefore be responsible for data-sharing, and the other company agrees. 6. Review of initial scores: Prior to public dissemination, initial scores will be provided to the companies for review. Companies will have 30 days in which to communicate explanations for not providing particular documents as specified in the Standard. For example, they may explain why particular trials should be excluded from the group of "Covered Trials". Companies may also correct minor deviations (such as missing links to a clinical trial registry) and amend their policies to align with this standard during this time. The GPS Project team will review submissions from companies and adjust scores as appropriate following the 30-day period.
Key Definitions
1. Analysis-ready dataset: a dataset of clinical trial data with a structure and content that allows statistical analysis to be performed with minimal programming (i.e., no complex data manipulations such as transformations or transpositions are required).
[1] The analysis-ready dataset typically includes participant characteristics, outcomes data, adverse event data, and exploratory data. It includes derived variables, or new variables generated mathematically for use in later analyses (for example, patient age calculated from birth dates). After the trial has been declared complete and the editing and cleaning process is done, the data are moved into an analyzable data file. If the study is blinded (or masked), the treatment code file is typically merged with the analyzable data file, and the data are unblinded to the investigators. Some or all of this nowunblinded dataset is then used for data analyses, although some of the data may never be used. [2] Ideally, analysis-ready datasets will be in ADaM format and meet CDISC standards, but this is not always the case, particularly for older trials.
Clinical study report (CSR):
The integrated written description of a study of an therapeutic, prophylactic, or diagnostic agent conducted in human subjects that is submitted to the product regulator. This document, which typically (but not always) follows CDISC and ICH format, combines the clinical and statistical description, presentations, and analysis into a single report. [3] [4] [5] Appendices may be included which contain the protocol, sample case report forms, technical statistical documentation, patient data listings, technical statistical details such as derivations, computations, analyses, and computer output, and other information. For data sharing purposes, it may be necessary to redact some information in the CSR in order to minimize the risk of patient reidentification. 
Dataset codebook/dictionary:
Study protocol:
A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term "protocol" refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [7] 6. Statistical analysis plan: A document that contains a more technical and detailed elaboration of the principal features of the analysis described in the protocol, and includes detailed procedures for executing the statistical analysis of the primary and secondary variables and other data [ICH E9]. [8] 7. Clinical study report synopsis: A summary of the efficacy evaluation (suggested to be primarily in table form). The synopsis should contain a full report of information related to safety and enough information to allow product regulators to fully assess whether the efficacy results, if any, cast doubt on the effectiveness of the product for the proposed indication. [9, 10] 
Methodological Note
This Standard was developed over a 2 year-period and finalized for its first application in March 2018. The development process consisted of the following: 2. The team generated a draft standard based on this review. Our objective was to arrive at requirements that (1) ensure the availability of sufficient information to achieve the major potential benefits of data sharing; (2) adopt requirements that companies could meet without undue burden or disadvantage; and (3) ensure that adherence to the Standard could be reliably measured. Given the expertise and depth of analysis conducted by the IOM Committee, our presumption was that the IOM's recommendations should be followed absent a strong reason to do otherwise. For example, one such reason might be practical problems with measuring adherence.
3. The draft Standard was sent to 11 experts from outside of the biopharmaceutical industry for review and comment. Reviewers included academic experts and representatives from FDA, medical journals, and existing repositories of clinical trial information. Their written feedback was discussed and revisions to the Standard were made in response.
4. The proposed Standard was introduced at a Roundtable for pharmaceutical companies convened by the project in March 2017 and a discussion was held with the companies in attendance, as well as at a Roundtable for patient groups in October of 2017.
5. Following revisions to the Standard, participating companies and the Clinical Study Data Request group were provided with an updated draft and invited to submit written comments. Comments were received from 11 companies.
6. A series of team conference calls were held in which each comment from the companies was considered and a response drafted. Extensive revisions were made to the draft Standard in response.
7. Throughout the development period, the Standard was pilot tested to ensure feasibility of measuring adherence. 
Sampled drugs and companies
We examined clinical trials relating to new molecular entities (NMEs), and new combination drugs containing at least one NME component, that were approved by the FDA in 2014.
[reference omitted] We confined our analysis to new drug applications (NDA) that were sponsored by the 20 largest biotechnology and pharmaceutical companies, or their subsidiaries, as measured by 2014 market capitalisation ranking.[reference omitted] We began with large companies to highlight practices among those with the most resources available to deploy toward satisfying transparency standards that are more comprehensive than those currently imposed by law. Subsidiaries and parent companies were identified by searching corporate websites, press releases and SEC filings and via communications with companies during the data validation process. Future versions of our scorecard will expand the analysis to include all trial sponsors, including small-sized and medium-sized companies and public sponsors.
Sampled clinical trials
A list of every clinical trial included in the NDA was created by reviewing the 2014 FDA approval packages for each of the 19 drugs. Basic characteristics of each trial were extracted (details in the online supplementary appendix 2). We excluded trials terminated without enrolment, expanded access trials, observational studies and trials that were ongoing or not at least 1 year past their primary completion date (PCD) by our study cut-off date of 1 February 2016. PCD was defined as on ClinicalTrials.gov. Observational studies (which constituted 5 of the 553 studies we reviewed) were generally excluded because they were ongoing at the time of our study cut-off date. Additionally, they are not covered under FDAAA legal requirements to report trial results.
From this 'all-trials' sample, we then selected two subsamples. The 'trials-in-patients' subsample was confined to trials conducted in patients (as opposed to healthy volunteers). The 'FDAAA trials' subsample was limited to trials subject to mandatory registration and results reporting under FDAAA. Because our analyses examine both legal compliance with FDAAA and satisfaction of a more aspirational standard, different samples of trials were required.
The legal requirements under FDAAA for reporting trial results apply only to 'controlled clinical investigations(s), other than a phase I clinical investigation' 30 of a drug that is the subject of an approved NDA or for which an NDA would be required in order for the drug to be legally marketed in the USA. The requirements apply only if the trial began after 27 September 2007 or was ongoing as of 26 December 2007. Finally, the trial must meet one of the following conditions: (1) at least one US site, (2) conducted under an FDA investigational new drug application, or (3) involve a drug, biologic or device manufactured in USA or its territories, and exported for research.[references omitted]
Data collection methods
Search terms to match trials in the registries included the trial's organisational identification number, product name, chemical name(s), number of participants and other characteristics captured from the FDA approval packages. We abstracted all available characteristics on each trial from the registry (details in the online supplementary appendix 2). We matched trials to journal articles using a minimum of three trial characteristics, and searched the registries for links to publications.
For each trial, data were retrieved by at least two research assistants who received training and worked independently (details in the online supplementary appendix 3). Discrepancies between coders' findings were resolved by consensus. Final datasets and findings were sent to drug companies for validation (details in the online supplementary appendix 4). Feedback from companies was generally incorporated into findings if it could be validated through our public sources. For example, companies in some cases provided a web link to a publication missed in our matching process.
The study did not undergo Institutional Review Board (IRB) review because it was not human subjects research.
Outcome measures
Our first outcome measure examined whether the trials in our samples were registered in any public registry, including corporate and international registries. Second, we determined whether either trial results or a clinical study report (CSR) synopsis were provided in the registry. Third, we determined whether each trial was published in a journal indexed by PubMed, Google Scholar or EMBASE. Fourth, we deemed each trial 'publicly available' if it had results reported in a registry, a CSR synopsis provided in a registry or results published in a journal.
Results were considered available if received by a registry or published by 1 February 2016. This date was chosen to provide a generous period of time for reporting results: at least 1 year after FDA approval of the drug plus a 1-month grace period.
We also measured the availability of trial results at the time each drug was approved by the FDA, 3 months after approval and 6 months after approval to track reporting timelines. Additionally, we tracked where trials were registered, reported or had shared CSRs to get a sense of the overall use of corporate, national and international registries and the need to invest in linking multiple databases together.
We applied these measures to two different samples of trials (table 1): (1) all trials, including trials enrolling healthy volunteers and patients, and (2) only trials enrolling patients. The alltrials analysis evaluates companies against the World Medical Association 12 recommendation that all trials be registered and have results disclosed to honour ethical obligations to research subjects, both healthy volunteers and patient participants, as described in the Declaration of Helsinki and Belmont Report. The Belmont Report defines research as, 'an activity designed… to develop or contribute to generalizable knowledge', which generally requires the dissemination of research results. In contrast, companies generally only commit to disclosing results for trials enrolling patients, not healthy volunteers, as expressed in their trade association codes of conduct. Therefore, we also applied our transparency standards to those trials that enrolled patients in the intent-to-treat population. That analysis excluded patients with renal or hepatic impairment (who did not have the condition being studied) and trials in healthy volunteers.
We also assessed the extent to which trials subject to FDAAA met that statute's transparency requirements. Setting cut-off points for this analysis was complex because there is a disagreement among companies about what the statute requires. There is broad agreement that FDAAA requires trial registration within 21 days after enrolling the first participant (we gave sponsors a 7-day grace period to account for delayed postings, weekends, holidays and time zones). However, two views exist about when results must be reported, both of which are plausible. One interpretation, which we call the 'trial completion date' view, is that results generally must be reported within 12 months after a trial's PCD, but may be delayed until 30 days after FDA approval if a company files a 'certificate of delay' with the NIH. 8 The other is that trial results are not due until 30 days after FDA approval of a new drug for an initial use approval. The Final Rule, a regulation released in September 2016 by the NIH and HHS, clarifies that trial results must be reported for both approved and unapproved indications, however, its effective date postdates the trials in our sample. 21 We examined compliance with FDAAA among applicable trials using both interpretations and used the 'approval date' interpretation in calculating company rankings.
Lastly, we ranked NDA sponsors by their overall clinical trial transparency. For pharmaceutical companies with only one drug approved by the FDA in 2014, we averaged their scores on (1) the trials-in-patients analysis, excluding trials in healthy volunteers, and (2) a FDAAA compliance standard that counted a trial as compliant if it satisfied either interpretation of the reporting requirements. For companies with multiple drugs approved, we pooled the trials from all drugs and then calculated the percentages of trials satisfying each of the two standards. In rare cases, we excluded trials (n=12) from a particular company ranking if the NDA sponsor was not the trial sponsor and therefore not responsible for publicly reporting trial results. If the responsible party was a ranked company, and we could confirm they were indeed the responsible party, we transferred the trials to their denominator and included them in their rankings.
Statistical analysis
Summary statistics (medians and interquartile ranges) were calculated to show how commonly trials for each approved drug and drug company met the transparency measures. All data were collected and analysed in Microsoft Excel V.15.18 (Redmond, Washington, USA).
Validation
Datasets and results were sent to the NDA holders of each drug for validation (details in the online supplementary appendix 4). Nine of 11 evaluated companies participated in both the validation process and a meeting to discuss study methods and findings (details in the online supplementary appendix 5), affording validation for 79% of drugs reviewed. Validated results are presented below.
4. Sensitivity analysis: effect of using primary completion (PCD) date rather than completion date (CD) to benchmark data-sharing practices (using data prior to 30-day widow to change practices) *Allergan acquired Avycaz, Kybella, Viberzi, and Vraylar before FDA approval. The company notes that for each of these drugs, results submission are in process for any trials without results on ClinicalTrials.gov. One trial for Kybella posted results 3 days late and was counted as compliant. Two trials for Avycaz were sponsored by AstraZeneca; Pfizer is now responsible to submit results. **In 2016, Odomzo was acquired by Sun Pharmaceuticals. + There have been disagreements on interpreting reporting requirements under FDAAA. Originally, disagreements were around whether FDAAA required controlled trials or all interventional trials to have reported results. Debates then extended to whether results were to be reported one year past a trial's PCD or 30 days post approval of the studied indication, if a certificate of delay was filed requesting reporting be extended to post FDA approval. Since the Final Rule took effect on January 18, 2017, clarifying FDAAA requirements, ClinicalTrials.gov states that no trials with PCDs on or before January 17, 2017 were required to report results, regardless of whether the product studied received FDA approval. Here, we include analyses based on the old interpretation because interpretations are still being contested and so ranking results and evaluations can be compared over time. Company's policy specifies data will be made available by compliance deadline (20% of score)
